At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 129 enrolled
Drug / intervention
Belinostatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Belinostat for Peripheral T-cell Lymphoma. Completed, enrolled 129 participants across 117 sites in 17 countries.
Detailed Summary
The purpose of this study is to assess efficacy and safety of belinostat in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL), who failed at least one prior systemic therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral T-cell Lymphoma
CountriesBelgium, Canada, Croatia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Russia, Slovakia, South Africa, Spain, United Kingdom, United States
CollaboratorsValerio Therapeutics
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedMar 2009
Primary CompletionNov 2013
Study CompletionOct 2014
TodayJul 2026
First PostedMar 20, 2009
Enrollment StartDec 15, 2008
Primary CompletionNov 5, 2013
Study CompletionOct 27, 2014
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 17.3 years ago
Interventions
Belinostatdrug